Home | Business News | CBJ Newsmakers | Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors CBJ Newsmakers RecommendedClear Blue Technologies International Announces Shares for Debt Transaction and Annual Incentive Compensation AwardsYamana Gold Announces Filing of Technical Report for JacobinaNexTech AR Solutions Files Amended MD&A for the Year ended December 31, 2019
